These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21993845)

  • 21. New advances in ovarian cancer.
    Liu J; Matulonis UA
    Oncology (Williston Park); 2010 Jul; 24(8):721-8. PubMed ID: 20718251
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of PARPis with Angiogenesis Inhibitors and Chemotherapy for Maintenance in Ovarian Cancer: A Network Meta-Analysis.
    Feng Y; Huang H; Wan T; Zhang C; Tong C; Liu J
    Adv Ther; 2019 Dec; 36(12):3368-3380. PubMed ID: 31599396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management and Treatment of Recurrent Epithelial Ovarian Cancer.
    Armbruster S; Coleman RL; Rauh-Hain JA
    Hematol Oncol Clin North Am; 2018 Dec; 32(6):965-982. PubMed ID: 30390768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.
    Ledermann JA; Hackshaw A; Kaye S; Jayson G; Gabra H; McNeish I; Earl H; Perren T; Gore M; Persic M; Adams M; James L; Temple G; Merger M; Rustin G
    J Clin Oncol; 2011 Oct; 29(28):3798-804. PubMed ID: 21859991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
    Dhillon S
    BioDrugs; 2013 Aug; 27(4):375-92. PubMed ID: 23728884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of Cediranib in ovarian cancer.
    Orbegoso C; Marquina G; George A; Banerjee S
    Expert Opin Pharmacother; 2017 Oct; 18(15):1637-1648. PubMed ID: 28933580
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging therapies: angiogenesis inhibitors for ovarian cancer.
    Jackson AL; Eisenhauer EL; Herzog TJ
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):331-46. PubMed ID: 26001052
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted agents and combinations in ovarian cancer: where are we now?
    McLachlan J; Lima JP; Dumas L; Banerjee S
    Expert Rev Anticancer Ther; 2016; 16(4):441-54. PubMed ID: 26942837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer.
    van der Bilt AR; de Vries EG; de Jong S; Timmer-Bosscha H; van der Zee AG; Reyners AK
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):224-42. PubMed ID: 22525643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma--mechanistics, review of phase III randomized clinical trials, and regulatory implications.
    Eskander RN; Tewari KS
    Gynecol Oncol; 2014 Feb; 132(2):496-505. PubMed ID: 24316305
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metronomic chemotherapy in ovarian cancer.
    Garg V; Kumar L
    Cancer Lett; 2023 Nov; 579():216469. PubMed ID: 37923056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent disease.
    Monk BJ; Pujade-Lauraine E; Burger RA
    Ann Oncol; 2013 Dec; 24 Suppl 10():x53-x58. PubMed ID: 24265406
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer relapse: From the latest scientific evidence to the best practice.
    Luvero D; Plotti F; Aloisia A; Montera R; Terranova C; Carlo De Cicco Nardone ; Scaletta G; Lopez S; Miranda A; Capriglione S; Gatti A; Pierluigi Benedetti Panici ; Angioli R
    Crit Rev Oncol Hematol; 2019 Aug; 140():28-38. PubMed ID: 31176270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
    Chung C; Lee R
    J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Emerging role of pemetrexed in ovarian cancer.
    Tomao F; Panici PB; Frati L; Tomao S
    Expert Rev Anticancer Ther; 2009 Dec; 9(12):1727-35. PubMed ID: 19954283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
    Ozols RF
    J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
    [No Abstract]   [Full Text] [Related]  

  • 37. Experience with bevacizumab in the management of epithelial ovarian cancer.
    Burger RA
    J Clin Oncol; 2007 Jul; 25(20):2902-8. PubMed ID: 17617521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [No available].
    Sabourin G
    Perspect Infirm; 2016; 13(2):59. PubMed ID: 27158729
    [No Abstract]   [Full Text] [Related]  

  • 39. The promise and perils of 'targeted therapy' of advanced ovarian cancer.
    Markman M
    Oncology; 2008; 74(1-2):1-6. PubMed ID: 18536523
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.
    Choi HJ; Armaiz Pena GN; Pradeep S; Cho MS; Coleman RL; Sood AK
    Cancer Metastasis Rev; 2015 Mar; 34(1):19-40. PubMed ID: 25544368
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.